Call for papers: Targeted therapies and ADCs in malignant hematology
Taylor & Francis is pleased to invite you to submit your work to an upcoming Article Collection exploring…
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines, Inc. FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026…